Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu

References

Page 1

	Year	Citations
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib Thomas J. Lynch, Daphne W. Bell, Raffaella Sordella, New England Journal of Medicine	2004	11.4K
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, New England Journal of Medicine	2009	8.2K
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer Frances A. Shepherd, José Rodrigues Pereira, Tudor–Eliade Ciuleanu, New England Journal of Medicine	2005	5.4K
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models D Li, Lauren Ambrogio, Takeshi Shimamura, Oncogene Systems BiologyMedicineBronchial NeoplasmIrreversible Egfr/her2 InhibitorCancer Treatment	2008	1.4K
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Robert Pirker, Jose R. Pereira, Aleksandra Szczęsna, The Lancet MedicineMetronomic TherapyPhase Iii TrialBronchial NeoplasmCancer Treatment	2009	1.4K
Intragenic ERBB2 kinase mutations in tumours Philip Stephens, Chris Hunter, Graham R. Bignell, Nature Tumor BiologyReceptor Tyrosine KinaseCancer GeneticsMedicineCell Biology	2004	785
Somatic Mutations of the <i>HER2</i> Kinase Domain in Lung Adenocarcinomas Hisayuki Shigematsu, Takao Takahashi, Masaharu Nomura, Cancer Research	2005	672
HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors Shizhen Emily Wang, Archana Narasanna, Marianela Pérez-Torres, Cancer Cell Signal TransductionSignaling PathwayCell RegulationMedicineReceptor Tyrosine Kinase	2006	464
Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI’s Lung Cancer Mutation Consortium (LCMC). Mark G. Kris, B. E. Johnson, D J Kwiatkowski, Journal of Clinical Oncology Surgical OncologyCancer PathologyCancer ManagementLung AdenocarcinomaImmunology	2011	213
HER2 <sup>YVMA</sup> drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy Samanthi A. Perera, Danan Li, Takeshi Shimamura, Proceedings of the National Academy of Sciences ImmunologyPathologyCancer BiologyRapid DevelopmentTumor Biology	2009	178

Page 1